Atomo Diagnostics (ASX:AT1) secured an agreement to supply its HIV self-test kit to UK-based Newfoundland Diagnostics, valued at AU$5.4 million over five years, according to a Tuesday filing with the Australian bourse.
The agreement, running until June 30, 2030, grants Newfoundland exclusive distribution rights for the company's tests in the UK and non-exclusive rights for the EU and Colombia, the filing said.
Atomo Diagnostics shares rose nearly 6% in midday trade Tuesday.
Price (AUD): $0.02, Change: $+0.0010, Percent Change: +5.56%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.